Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.



Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.

Contact SupportLog In

$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 18 | 2025CMS Price Negotiation Update; Ypsomed and CamDiab Launch mylife Loop on iOSPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 17 | 2025Obesity Spotlight: Can BI Step Outside of Lilly's Shadow?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA + Basal, Other, Topics Mar 12 | 2025Roche is a Zeal-ot for PetrelintidePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 10 | 2025Obesity Spotlight: Zealand’s Path to Find a PartnerPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 28 | 2025Tandem, Altimmune, MannKind, Silence, and Viatris Q4 ’24 Earnings; Zevra Sells PRV; TIXiMED Ph1 TIX100 Trial UpdatePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i, Topics Feb 25 | 2025Lilly Stockpiles Orfoglipron; February CHMP Agenda ObservedPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 21 | 2025Sema Shortage Resolved; Pfizer/Viking M&A Rumor; Insulet Q4 ’24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 20 | 2025Zealand FY Q4 ‘24 Earnings; Steve Pacelli Leaves DexcomPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Feb 19 | 2025New Tandem AID Algorithm TrialPurchase Blast
1 2 3 4 100